Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | March 2011 |
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Concurrent chemotherapy and radiation therapy (chemoRT) has become the standard of care for
treatment of many patients with advanced head and neck squamous cell carcinoma (HNSCC),
though many clinical questions remain. Prior experience has revealed locoregional control
(LRC), disease free survival (DFS) and overall survival (OS) at 3 years exceeding 80% after
treatment with the use of hyperfractionated intensity modulated radiation therapy (IMRT) and
concurrent weekly cisplatin chemotherapy for patients with locally advanced HNSCC. This
multi-institutional phase II ZCC00204 trial resulted in an acceptable quality of life (QOL)
and toxicity profile. The current trial is an attempt to maintain high LRC, while further
minimizing both acute and chronic toxicities, and maximizing QOL.
treatment of many patients with advanced head and neck squamous cell carcinoma (HNSCC),
though many clinical questions remain. Prior experience has revealed locoregional control
(LRC), disease free survival (DFS) and overall survival (OS) at 3 years exceeding 80% after
treatment with the use of hyperfractionated intensity modulated radiation therapy (IMRT) and
concurrent weekly cisplatin chemotherapy for patients with locally advanced HNSCC. This
multi-institutional phase II ZCC00204 trial resulted in an acceptable quality of life (QOL)
and toxicity profile. The current trial is an attempt to maintain high LRC, while further
minimizing both acute and chronic toxicities, and maximizing QOL.
Inclusion Criteria:
- Biopsy proven squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, or
larynx
- No surgical resection of primary site or neck dissection (excisional biopsy of lymph
node is permitted)
- Human Papilloma Virus (HPV) testing of tumor performed; HPV p16 by
immunohistochemistry
- Stage III or IVa disease (T1-2N1-3M0, T3-4N0-3M0) excluding T1-2N1 oral cavity and
tonsil primaries and any N2C or bilateral N3 disease. Patients with T2N0 cancer of
the base of tongue and hypopharynx are eligible
- ECOG performance status 0-1
- Age >18 years
- No current pregnancy
- No other invasive malignancies within the last 2 years Patients with basal cell or
squamous cell skin cancers or carcinoma in situ of any site are eligible.
- No prior radiotherapy to the head and neck region
- No prior cisplatin chemotherapy
- No symptomatic coronary disease or myocardial infarction within the last 6 months
- Laboratory evaluation: ANC > 2,000/mm3, platelets >100,000/mm3, creatinine < 1.5
mg/dl, creatinine clearance > 50 ml/min, bilirubin < 1.5 mg/dl, AST or ALT < 2X upper
normal limit
- Study-specific consent signed prior to entry
Exclusion Criteria:
- Second primary malignancy that is clinically detectable
- Inability or unwillingness to comply with chemoRT
- Prior radiotherapy, chemotherapy, or investigational treatment for squamous cell
carcinoma of head and neck.
- Metastatic disease (M1)
- Pregnant or breast-feeding women.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials